8-K: Viridian posts strong Phase 3 data for TED autoinjector

Viridian reported highly significant Phase 3 REVEAL-1 results for subcutaneous elegrobart in active thyroid eye disease, outlined near-term veligrotug PDUFA on June 30, 2026, and reiterated cash runway to profitability.

Summary

• REVEAL-1 (n=132) met the primary endpoint: Q4W proptosis responder rate (PRR) 54% vs 18% placebo at week 24 (p < 0.0001); Q8W PRR 63% vs 18% (p < 0.0001).
• Key Q4W secondary: mean proptosis change −2.33 mm vs −0.81 mm placebo (p < 0.0001); diplopia responder 71% vs 32% (p = 0.0009); diplopia complete resolution 51% vs 16% (p = 0.0013).
• Q8W secondary outcomes: mean proptosis change −2.50 mm vs −0.81 mm (p < 0.0001); diplopia responder 54% vs 32% (p = 0.05; nominal); diplopia complete resolution 28% vs 16% (p = 0.14; not significant).
• MRI assessments corroborated exophthalmometry: Q4W MRI PRR 50% vs 2% placebo; Q8W MRI PRR 36% vs 2% (both p < 0.0001).
• Safety: generally well tolerated; placebo-adjusted hearing impairment AE rates low (Q4W 11.3%, Q8W 2.3%), with events reported as tinnitus only and no hearing loss.
• REVEAL-2 (chronic TED) topline remains on track for Q2 2026; Biologics License Application (BLA) for elegrobart anticipated in Q1 2027.
• Veligrotug (IV IGF‑1R) BLA under FDA Priority Review with a PDUFA target action date of June 30, 2026; product previously received Breakthrough Therapy Designation and Priority Review in 2025.
• Cash and investments: $875 million as of December 31, 2025; management expects cash, potential near-term DRI royalty milestones, and anticipated revenues from veligrotug and elegrobart (if approved) to fund through profitability.
• Market context: the only marketed TED therapy requires eight IV infusions and generated roughly $2B annualized revenue in 2025; a subcutaneous, at-home autoinjector could expand treatment access if approved.

Sentiment

Score: 8

Explanation: StockSavvy.ai views the statistically robust Phase 3 data, low AE profile, and clear regulatory milestones as meaningfully de-risking; remaining regulatory and commercial execution risks temper a higher score.

Positives

• Primary and key secondary endpoints achieved with high statistical significance for Q4W dosing (PRR 54% vs 18%; mean proptosis −2.33 mm vs −0.81 mm; all p < 0.0001).
• Q8W dosing also showed strong proptosis efficacy (PRR 63% vs 18%; mean proptosis −2.50 mm vs −0.81 mm; p < 0.0001), suggesting efficacy with as few as three injections.
• Clinically meaningful diplopia benefits in Q4W (responder 71% vs 32%; complete resolution 51% vs 16%).
• Safety profile generally favorable with low, tinnitus-only hearing impairment rates (placebo-adjusted 11.3% Q4W; 2.3% Q8W) and mostly mild AEs.
• Clear regulatory path: REVEAL-2 topline in Q2 2026 and elegrobart BLA planned for Q1 2027; veligrotug PDUFA on June 30, 2026 under Priority Review.
• $875M cash at 12/31/2025 and expected DRI milestone and potential product revenues support funding through profitability.
• Commercial leverage: veligrotug launch infrastructure expected to support elegrobart with limited incremental spend if approved.

Negatives

• Some secondary endpoints did not achieve statistical significance in Q8W (diplopia complete resolution p = 0.14) and Q4W CAS reduction (p = 0.24).
• Adverse events common in active arms (e.g., muscle spasms up to 41%, injection site reactions up to 34%), albeit largely mild and class-consistent.
• Elegrobart BLA timing (Q1 2027) places revenue contribution further out, increasing dependence on successful veligrotug launch near term.
• Funding outlook depends on regulatory approvals and milestone receipts, which are inherently uncertain.

Risks

• Clinical results from REVEAL-1 may not predict outcomes in REVEAL-2 or future studies; ongoing and future trials may not support regulatory submissions.
• Regulatory timing and approvals are uncertain and may be delayed, including potential delays related to prolonged government shutdowns.
• Manufacturing risks could impact development timelines or product availability.
• Competition from other therapies or products for TED may limit market share.
• Market size estimates and commercial uptake are uncertain; products may not be commercially successful even if approved.
• Changes to trial protocols, enrollment pace, or data timing could occur.
• Sufficiency of cash, cash equivalents, and short-term investments depends on multiple factors including milestones and approvals.
• Intellectual property position and protection may affect competitive advantage.

Future Outlook

Management targets REVEAL-2 topline data in Q2 2026 and plans to submit an elegrobart BLA in Q1 2027; veligrotug remains under Priority Review with a June 30, 2026 PDUFA target. If approvals are secured, Viridian expects to leverage a largely built commercial infrastructure and, together with existing cash and potential DRI milestones, fund operations through profitability.

Management Comments

• “REVEAL-1 met its primary endpoint with high statistical significance... Elegrobart treatment drove robust proptosis responses in a regimen of as few as three subcutaneous doses,” said Steve Mahoney, President and CEO.
• Mahoney emphasized the opportunity for an at-home, self-administered treatment in a ~$2B market currently served by an eight-infusion IV therapy.
• “Subcutaneous elegrobart showed rapid and clinically meaningful reductions in proptosis and diplopia with a convenient, well-tolerated dosing profile,” said Prem Subramanian, MD, PhD, underscoring potential to reach more patients than an IV therapy.

Industry Context

StockSavvy.ai notes that an effective subcutaneous IGF‑1R therapy would be a meaningful advance versus the current IV standard in TED (Amgen’s teprotumumab), aligning with broader biopharma trends favoring at-home autoinjectors for chronic autoimmune conditions. Positive topline data, coupled with a near-term IV entrant (veligrotug), positions Viridian to compete across both infusion and SC segments in a roughly $2B and expanding TED market.

Comparison to Industry Standards

• Elegrobart efficacy aligns with class-leading IGF-1R results: PRR 54–63% (SC) at 24 weeks vs Viridian’s IV veligrotug PRR of 56% (chronic, THRIVE-2) and 70% (active, THRIVE) at 15 weeks, per the corporate deck.
• Mean proptosis reduction is consistent with leading IV data: elegrobart −2.33 to −2.50 mm vs veligrotug −2.34 mm (THRIVE-2) to −2.89 mm (THRIVE) at 15 weeks.
• Diplopia outcomes: elegrobart Q4W achieved 51% complete resolution in active TED (24 weeks) vs veligrotug 54% complete resolution in active TED at 15 weeks.
• Safety profile within class expectations with low tinnitus-only hearing AEs: elegrobart placebo-adjusted 11.3% (Q4W) and 2.3% (Q8W) vs veligrotug placebo-adjusted rates of 5.5% (active, THRIVE) and 9.6% (chronic, THRIVE-2).
• Administration convenience: elegrobart offers SC autoinjector every 4 or 8 weeks (as few as three doses) compared with eight IV infusions required by the currently marketed therapy, potentially expanding patient access and adherence.

Stakeholder Impact

• Shareholders: material clinical de-risking and a multi-asset TED portfolio may improve risk-adjusted value ahead of key regulatory events.
• Patients: potential first at-home subcutaneous autoinjector option offering meaningful improvements in proptosis and diplopia, if approved.
• Physicians: additional TED treatment modality (SC and IV options) could broaden access and tailor therapy by patient need.
• Payers: potential for expanded treatment access; pricing and utilization dynamics to be assessed against existing IV standard.
• Employees/Commercial Partners: launch-readiness and portfolio leverage support operational scaling across TED therapies.

Next Steps

• Deliver REVEAL-2 (chronic TED) topline data in Q2 2026.
• Advance elegrobart toward BLA submission in Q1 2027.
• Prepare for potential veligrotug U.S. approval by June 30, 2026 and commercial launch readiness.
• Leverage veligrotug commercial infrastructure to support an elegrobart launch, if approved.

Key Dates

Recommendation

The Phase 3 REVEAL-1 data are strongly positive with compelling efficacy and a manageable safety profile, reinforcing elegrobart’s potential as the first SC autoinjector in TED. Coupled with veligrotug’s near-term PDUFA, cash of $875M, and anticipated milestones, the risk-reward skews favorable despite customary regulatory and launch execution risks.

Keywords

Viridian Therapeutics, elegrobart, REVEAL-1, thyroid eye disease, IGF-1R antibody, subcutaneous autoinjector, proptosis responder rate, diplopia, veligrotug, PDUFA, Priority Review, Breakthrough Therapy, BLA submission, VRDN, biotech clinical trial